Anavex Life Sciences Corp (AVXL)

[indialong]

https://247wallst.com/healthcare-business/2019/06/18/two-very-speculative-biotechs-with-promising-alzheimers-treatment-hopefuls/

"ANAVEX 2-73 modulates muscarinic acetylcholine receptors (mAChRs) in addition to S1R. Activation of both receptors produces synergistic effects and leads to further enhanced neuroprotection. A high concentration demonstrated statistically significant separation in clinical benefit from a low concentration in a Phase IIa study after only five weeks of treatment. The treatment period was extended upon patient request and efficacy was maintained after 148 weeks of treatment… We project ANAVEX 2-73 use only in patients with mild AD and forecast peak U.S. market penetration to be below 10%. We reach U.S. sales of over $1.5 billion in 2032, which we believe should be conservative when compared to historical sales of FDA-approved treatments for AD."